



1/17



Fig. 1



2/17


Fig. 2

3/17


Fig. 3**A. IL-12 p40****B. IFN- γ** 

4/17


Fig. 4



5/17


Fig. 5

6/17


Fig. 6

7/17


Fig. 7



8/17







Fig. 8

9/17


Fig. 9

10/17

Fig. 10


	skin		lymph node
	1 day	5 day	1day
control			
oligo-4(O)			

11/17

Fig. 11


12/17

Fig. 12




13/17


Fig. 13




14/17

Fig. 14

15/17

Fig. 15

16/17

Fig. 16

17/17

Fig. 17